Underscoring the massive scale of America’s medical debt problem, a New York-based nonprofit has struck a deal to pay off old medical bills for an estimated 20 million people. Undue Medical Debt, which buys patient debt, is retiring $30 billion worth of unpaid bills in a single transaction with Pendrick Capital Partners, a Virginia-based debt…
Biogen’s Apellis Pharmaceuticals acquisition comes nearly two years after the drugmaker purchased immunology startup Human Immunology Biosciences. CEO Chris Viehbacher said Apellis accelerates Biogen’s expansion in nephrology, supporting a HI-Bio drug currently in pivotal testing for three kidney conditions. The post Why Biogen Is Paying $5.6B to Buy Apellis Pharma appeared first on MedCity News.
Without clear goals and shared accountability, AI pilots can quickly become exercises in hope rather than strategy. The post ‘Free’ AI Pilots Are Costing Health Systems Millions appeared first on MedCity News.
Socktober Shatters Records Again! “Socktober” continues to be a celebrated and engaging campaign for Compass One Healthcare associates across the country. This year, we’re proud to share that we not only met, but exceeded, our goals by collecting and donating more than 300,000 pairs of socks to charities nationwide. Crothall teams played a major role in this year’s effort, with more…
The National Institutes of Health has lost thousands of workers since President Donald Trump began his second term. Among them: scientists who pioneered cancer treatments, researched tick-borne diseases, or worked to prevent tobacco use. We spoke to a half dozen scientists who said they left the agency because of the tumult of 2025 and talked…
When congressional Republicans in 2017 pushed to repeal the Affordable Care Act and slash Medicaid, dozens of physician groups, patient advocates, hospitals, and others rallied to defend the law and the safety-net program. Eight years later, two industry groups have been notably restrained as GOP lawmakers consider sweeping new Medicaid cuts: the American Medical Association…
LB Pharmaceuticals’ planned IPO will fund late-stage clinical development of LB-102, a once-daily pill designed to improve on the old Sanofi schizophrenia drug Solian. The IPO filing follow a corporate restructuring in May that cut the jobs of LB’s chief financial and scientific officers to streamline operations and extend its cash runway. The post With…
The first Phase 3 results for Eli Lilly’s daily pill orforglipron show statistically significant reductions in blood sugar and body weight in patients with type 2 diabetes. The pharmaceutical giant plans global regulatory submissions starting at the end of this year. The post Eli Lilly’s Metabolic Medicine Takes the Lead in the Race to Develop…
Neurocrine Biosciences’ Crenessity is now FDA approved for treating classic congenital adrenal hyperplasia (CAH), a rare and potentially fatal endocrine disorder. The approval comes with a priority review voucher, which Neurocrine could sell for around $150 million. The post Neurocrine Lands FDA Nod for First New Treatment in Decades for Rare Endocrine Disorder appeared first…
The FDA approved Ionis Pharmaceuticals’ Dawnzera for preventing swelling attacks caused by the rare disease hereditary angioedema. A Takeda Pharmaceutical product dominates this market, but Ionis has clinical data showing patients had better outcomes after switching to Dawnzera from Takeda’s drug and other currently available HAE medications. The post In Crowded Market for a Rare…